Minimal Residual DiseasePhase 1NCT05601830
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
A Phase 1 study testing QN-030a, Cyclophosphamid and Fludarabine in people with Minimal Residual Disease, run by Institute of Hematology & Blood Diseases Hospital, China at 1 site in China.
Trial summary
This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in Acute Myeloid Leukemia Minimal Residual Disease(AML MRD). This clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-020a in patients with AML MRD, where a "3+3" enrollment schema will be utilized at dose… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Minimal Residual Disease
- What is being tested?
- QN-030a, Cyclophosphamid and Fludarabine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1 participants
- Where
- 1 siteChina
- Study dates
- 9 Oct 2022to 30 Jun 2023
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Provision of signed and dated informed consent form(ICF)
- ≥18 years old
- Subject diagnosed of AML MRD.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1
- Adequate organ function as defined in the protocol
- Donor specific antibody (DSA) to QN-030a: MFI ≤ 2000
Who cannot join
- Allergic to drug used in this study
- Accept other anti-tumor drug within 2 weeks of day 0 (first QN-030a dose infusion)
- Prior allogeneic hematopoietic stem cell transplant (HSCT) within 6 months of Day 0, received systemic immunosuppressive therapy within 7 days of Day 0, or likely to require systemic immunosuppressive therapy
- Acute Promyelocytic Leukemia (APL)
- Active central nervous system Leukemia.
- Uncontrolled, active clinically significant infection
Show all 11Show fewer
- Clinically significant cardiovascular disease as defined in the protocol
- History of central nervous system (CNS) disease such as stroke, epilepsy.
- Females are pregnant or lactating
- Known HIV infection, active Hepatitis B (HBV) or Hepatitis C (HCV) infection
- Investigator-assessed presence of any medical or social issues that are likely to interfere with study conduct or may cause increased risk to subject
Trial locations and contacts
1 site in 1 country.
China1 site
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality
About this study
Official title: Clinical Study on the Safety and Efficacy of QN-030a in Acute Myeloid Leukemia With Minimal Residual Disease
This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in Acute Myeloid Leukemia Minimal Residual Disease(AML MRD).
This clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-020a in patients with AML MRD, where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.
- Conditions
- Minimal Residual Disease
- Being tested
- QN-030a, Cyclophosphamid, Fludarabine, Cytarabine
- Medical subject headings
- Neoplasm, Residual
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QN-030aDrug
NK cell therapy
CyclophosphamidDrug
Lympho-conditioning Agent
FludarabineDrug
Lympho-conditioning Agent
CytarabineDrug
Lympho-conditioning Agent
| Study group | Role | What they receive |
|---|---|---|
| QN-030a | Experimental | QN-030a in Adult subjects with MRD Receives: Drug: QN-030a; Drug: Cyclophosphamid; Drug: Fludarabine; Drug: Cytarabine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Measured: 28 Days from first dose of QN-030a
Incidence of subjects with Dose Limiting Toxicities within each dose level cohort
Measured: 28 Days from first dose of QN-030a
Secondary outcomes (4)
Number of participants achieving MRD-
Measured: 28 Days from first dose of QN-030a
Relapse-free survival (RFS) of participants
Measured: Up to approximately 2 years after last dose of QN-030a
Overall survival (OS) of participants
Measured: Up to approximately 2 years after last dose of QN-030a
Determination of the pharmacokinetics (PK) of QN-030a cells in peripheral blood
he PK of QN-030a in peripheral blood will be reported as the relative percentage of product (QN-030a) DNA versus patient DNA (% chimerism) measured from blood samples at the specified time points
Measured: Up to approximately 2 years after last dose of QN-030a
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Nov 2022
- Study start9 Oct 2022
- Primary completion30 Jun 2023
- Study completion30 Jun 2023
Why it stopped: It did not reach the expected results of clinical trial
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Minimal Residual DiseaseStudies of the same condition, open and under way.
- More trials run by Institute of Hematology & Blood Diseases Hospital, ChinaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05601830
- Sponsor's protocol ID
- IIT2022030
- Status last verified
- May 2024
- First submitted
- 24 Oct 2022
- Last updated
- 6 Nov 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Study on the Safety and Efficacy of QN-030a in Acute Myeloid Leukemia With Minimal Residual Disease
- ClinicalTrials.gov ID
- NCT05601830
- Acronym / sponsor ID
- IIT2022030
- Conditions
- Minimal Residual Disease
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: It did not reach the expected results of clinical trial
- Enrolment
- 1 participants (actual)
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaUniversity, hospital or other
- Study start
- 9 Oct 2022 (actual)
- Primary completion
- 30 Jun 2023 (actual)
- Study completion
- 30 Jun 2023 (actual)
- First posted
- 1 Nov 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in Acute Myeloid Leukemia Minimal Residual Disease(AML MRD).
This clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-020a in patients with AML MRD, where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| QN-030a | Experimental | Drug: QN-030a, Drug: Cyclophosphamid, Drug: Fludarabine, Drug: CytarabineQN-030a in Adult subjects with MRD |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Provision of signed and dated informed consent form(ICF)
- ≥18 years old
- Subject diagnosed of AML MRD.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1
- Adequate organ function as defined in the protocol
Key exclusion criteria (11 listed)
- Allergic to drug used in this study
- Accept other anti-tumor drug within 2 weeks of day 0 (first QN-030a dose infusion)
- Prior allogeneic hematopoietic stem cell transplant (HSCT) within 6 months of Day 0, received systemic immunosuppressive therapy within 7 days of Day 0, or likely to require systemic immunosuppressive therapy
- Acute Promyelocytic Leukemia (APL)
- Active central nervous system Leukemia.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QN-030aNK cell therapy | Drug | QN-030a |
| CyclophosphamidLympho-conditioning Agent | Drug | QN-030a |
| FludarabineLympho-conditioning Agent | Drug | QN-030a |
| CytarabineLympho-conditioning Agent | Drug | QN-030a |
Primary outcome
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time frame: 28 Days from first dose of QN-030a
Incidence of subjects with Dose Limiting Toxicities within each dose level cohort
Time frame: 28 Days from first dose of QN-030a
4 secondary outcomes
Number of participants achieving MRD-
Time frame: 28 Days from first dose of QN-030a
Relapse-free survival (RFS) of participants
Time frame: Up to approximately 2 years after last dose of QN-030a
Overall survival (OS) of participants
Time frame: Up to approximately 2 years after last dose of QN-030a
Determination of the pharmacokinetics (PK) of QN-030a cells in peripheral blood
Time frame: Up to approximately 2 years after last dose of QN-030a
Results and safety
The study was stopped early (reason given: It did not reach the expected results of clinical trial). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2024.
- Individual participant dataSharing planned: No
Related trials for Minimal Residual Disease
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
RecruitingPhase 1
Vididencel in CML-CP Patients With MRD
CML (Chronic Myelogenous Leukemia)
RecruitingObservational study
Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNA
Non-Small Cell Lung Cancer, Minimal Residual Disease
Not yet recruitingPhase 2
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Not yet recruitingObservational study
Risk Stratification Value of Deep NGS-MRD Detection in Acute Myeloid Leukemia Patients After Allo-HSCT
Measurable Residual Disease, Acute Myeloid Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing QN-030a, Cyclophosphamid and Fludarabine in people with Minimal Residual Disease, run by Institute of Hematology & Blood Diseases Hospital, China at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 6 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: It did not reach the expected results of clinical trial). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (time frame: 28 Days from first dose of QN-030a). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2024.